NCT03530826 A Crowd Sourcing Platform for Patients With Cancer
| NCT ID | NCT03530826 |
| Status | Recruiting |
| Phase | — |
| Sponsor | All4Cure |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2018-04-26 |
| Primary Completion | 2028-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2018-04-26 with a primary completion date of 2028-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
All4Cure aims to accelerate learning about cancer by sharing medical information and research results from cancer patients with fellow cancer patients, oncologists, and scientists on the All4Cure website with the hope that together patients, clinicians and researchers can cure cancer faster.
Eligibility Criteria
Inclusion Criteria: * Have been diagnosed with cancer. * Be under the care of a physician. * Be 18 years of age or older. Exclusion Criteria:
Contact & Investigator
Carl A Blau, MD
PRINCIPAL INVESTIGATOR
All4Cure
Frequently Asked Questions
Who can join the NCT03530826 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03530826 currently recruiting?
Yes, NCT03530826 is actively recruiting participants. Contact the research team at tony@all4cure.com for enrollment information.
Where is the NCT03530826 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT03530826 clinical trial?
NCT03530826 is sponsored by All4Cure. The principal investigator is Carl A Blau, MD at All4Cure. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.